CHO Cells News and Research

RSS

Major biological resource centre increases cell line supply capacity with TAP’s automated cryovial filling system

The Automation Partnership (TAP), world leader in the design and development of innovative automation for life science applications announced its Fill-It™, benchtop automated dispensing system, is being used at one of the world's largest biological resource centres to improve the precision of filling and to significantly reduce the time required to dispense cells into large numbers of cryovials.

6 Jul 2010

New method to synthesize drug candidates for testing

Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group. However, the processes now used require harsh reaction conditions or only work in a small number of cases, limiting their usefulness for synthesizing new drug candidates for testing.

25 Jun 2010

Impact of oil spill on humans and wildlife

University of Rhode Island Pharmacy Professor Bongsup Cho knows there are cancer-causing chemicals in diesel fumes and cigarette smoke.

25 Jun 2010

Alnylam presents data on novel delivery lipids at IBC 6th Annual Cell Line Development and Engineering conference

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the IBC 6th Annual Cell Line Development and Engineering conference held in San Francisco, California from June 21 - 24, 2010.

24 Jun 2010

ASH selects 14 participants for 2010 MMSAP

The American Society of Hematology announces the selection of 14 participants for its 2010 Minority Medical Student Award Program, which encourages minority Medical students to purse an interest in hematology research. Award recipients will each receive the support of a research mentor and a career-development mentor, travel stipends to attend the ASH annual meeting, and a subscription to the scientific journal Blood, the official journal of ASH.

18 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

CrystalGenomics to merge with BexPharm

CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.

28 May 2010

CEVEC, Pevion Biotech sign license option agreement for transient CAP-T cell expression technology

CEVEC Pharmaceuticals, the German developer of a novel human expression system derived from amniocytes, announced today the signing of an exclusive license option agreement with Pevion Biotech, the Swiss vaccine company. The agreement enables Pevion Biotech to exclusively use CEVEC's transient CAP-T™ cell expression technology to manufacture and commercialize a protein antigen for vaccination against a widespread human infectious disease.

26 May 2010

Results of BioSante's 2A/Furin technology in industrial antibody CHO expression system announced

BioSante Pharmaceuticals, Inc. today announced that results of an evaluation of its 2A/Furin technology by Novartis Pharma AG in its industrial antibody CHO expression system were published in the Journal of Applied Microbiology & Biotechnology. The results demonstrate that the 2A/Furin technology was integrated successfully into a plasmid-based, industrial-scale, CHO antibody cell line development process, with minimal optimization required.

21 May 2010

BioGenes study documents insufficient sensitivity of ELISA-based generic HCP assay

BioGenes GmbH, a supplier of GMP-compliant immunoassays and antibodies, completed a study that documents the insufficient sensitivity of an ELISA-based generic host cell protein assay. The results confirm the observation of several contract manufacturers that generic HCP assays are only of limited use for detection of HCPs during manufacturing processes.

12 May 2010

CrystalGenomics completes European Phase I SAD study of CG400549 antibiotic candidate

CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe.

11 May 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2010, and company highlights.

6 May 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics, a division of Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new data at the Cell Culture Engineering XII conference held in Alberta, Canada from April 25 - 30, 2010. Alnylam Biotherapeutics was formed by Alnylam to develop RNAi technologies for application in manufacturing processes for biotherapeutic products, including recombinant proteins and monoclonal antibodies.

4 May 2010

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

3 May 2010

Symphogen's Sympress II technology demonstrates cost-effective single batch production of rpAb

Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print] demonstrating the ability of its Sympress II technology to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency that the Company believes could supply drug product for large indications such as cancer and infectious disease.

26 Apr 2010

Sirolimus-based immunosuppression improves survivals after transplantation for HCC

26 Mar 2010

New therapies increase survival rates in post-transplant liver cancer patients

A recent study found that sirolimus-based immunosuppression following liver transplantation in patients with non-resectable hepatocellular carcinoma (liver cancer) significantly increases survival rates for this patient population. Results of this study appear in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

25 Mar 2010

TAP to showcase ambr system at Cell Line Development and Engineering 2010

The Automation Partnership, a world leader in the design and development of innovative automation for life science applications, is pleased to announce it will be showcasing its new advanced micro bioreactor system (ambr™) at Cell Line Development and Engineering 2010, February 25-26 in San Francisco, USA.

15 Feb 2010

Discovery of new class of compounds may help fight hepatitis C

Stanford University School of Medicine scientists have discovered a novel class of compounds that, in experiments in vitro, inhibit replication of the virus responsible for hepatitis C. If these compounds prove effective in infected humans as well, they may dramatically accelerate efforts to confront this virus’s propensity to rapidly acquire drug resistance, while possibly skirting some of the troubling side effects common among therapies in current use and in late-stage development.

21 Jan 2010

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Several studies have shown that lipid peroxidation stimulates collagen production in fibroblasts and hepatic stellate cells (HSC), and plays an important role in the development of liver fibrosis. Hepatoprotective effects of green tea against carbon tetrachloride, cholestasis and alcohol induced liver fibrosis were reported in many studies. However, the hepatoprotective effect of green tea in dimethylnitrosamine (DMN)-induced models has not been studied.

18 Nov 2009